Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss

dc.contributor.authorLi, Qiyan
dc.contributor.authorYu, Hong
dc.contributor.authorZinna, Robert
dc.contributor.authorMartin, Kylie
dc.contributor.authorHerbert, Betthany
dc.contributor.authorLiu, Angen
dc.contributor.authorRossa Júnior, Carlos [UNESP]
dc.contributor.authorKirkwood, Keith L.
dc.contributor.institutionMedical University of South Carolina
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-08-06T16:12:50Z
dc.date.available2015-08-06T16:12:50Z
dc.date.issued2011
dc.description.abstractp38 mitogen-activated protein kinases (MAPKs) are critical for innate immune signaling and subsequent cytokine expression in periodontal inflammation and bone destruction. In fact, previous studies show that systemic p38 MAPK inhibitors block periodontal disease progression. However, development of p38 MAPK inhibitors with favorable toxicological profiles is difficult. Here, we report our findings regarding the contribution of the downstream p38 MAPK substrate, mitogen-activated protein kinase-activated protein kinase 2 (MK2 or MAPKAPK-2), in immune response modulation in an experimental model of pathogen-derived lipopolysaccharide (LPS)-induced periodontal bone loss. To determine whether small interfering RNA (siRNA) technology has intraoral applications, we initially validated MK2 siRNA specificity. Then, gingival tissue surrounding maxillary molars of rats was injected with MK2 siRNA or scrambled siRNA at the palatal regions of bone loss. Intraoral tissues treated with MK2 siRNA had significantly less MK2 mRNA expression compared with scrambled siRNA-treated tissues. MK2 siRNA delivery arrested LPS-induced inflammatory bone loss, decreased inflammatory infiltrate, and decreased osteoclastogenesis. This proof-of-concept study suggests a novel target using an intraoral RNA interference strategy to control periodontal inflammation.en
dc.description.affiliationMedical University of South Carolina, Department of Craniofacial Biology
dc.description.affiliationMedical University of South Carolina, Department of Microbiology and Immunology
dc.description.affiliationUnespUniversidade Estadual Paulista Júlio de Mesquita Filho, Departamento de Diagnóstico e Cirurgia, Faculdade de Odontologia de Araraquara
dc.format.extent633-642
dc.identifierhttp://jpet.aspetjournals.org/content/336/3/633.full
dc.identifier.citationThe Journal of Pharmacology and Experimental Therapeutics, v. 336, p. 633-642, 2011.
dc.identifier.doi10.1124/jpet.110.172395
dc.identifier.issn0022-3565
dc.identifier.lattes7634063102292261
dc.identifier.urihttp://hdl.handle.net/11449/125692
dc.language.isoeng
dc.relation.ispartofThe Journal of Pharmacology and Experimental Therapeutics
dc.relation.ispartofjcr3.706
dc.relation.ispartofsjr1,586
dc.rights.accessRightsAcesso restrito
dc.sourceCurrículo Lattes
dc.subjectInnate immunityen
dc.subjectCell signalingen
dc.subjectBone resorptionen
dc.subjectRANKLen
dc.subjectImmunologyen
dc.titleSilencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone lossen
dc.typeArtigo
unesp.author.lattes7634063102292261[7]
unesp.author.orcid0000-0003-1705-5481[7]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Odontologia, Araraquarapt
unesp.departmentDiagnóstico e Cirurgiapt

Arquivos